Pulmonary Fibrosis

Pulmonary Fibrosis Treatment

Pulmonary fibrosis treatment

Stem Cell Treatment for Pulmonary Fibrosis

For doctors treating people living with pulmonary fibrosis, the goal of treatment is to slow the decline of lung function, relieve breathing difficulties caused by lung scarring and encourage the best possible quality of life. Traditional approaches include anti-inflammatory medications, oxygen therapy and pulmonary rehabilitation. However, because each patient and condition is unique, the effectiveness of these treatments can vary widely.

The Lung Institute offers stem cell therapy as an alternative pulmonary fibrosis treatment. By harnessing the power of adult stem cells, this groundbreaking therapy may promote healing and improve lung function. Stem cells are unique in that they are undifferentiated, which means that they have the potential to self-renew, replicate and specialize to become any type of cell within the body, such as a lung cell. As such, stem cell therapy provides a new source of hope for some people who are seeking treatment for pulmonary fibrosis, many of whom rely on supplemental oxygen around the clock or face challenges in performing everyday tasks.

At the Lung Institute, patient safety and comfort are paramount. Our treatments are patient-centered, and they are designed and administered accordingly. We perform minimally invasive stem cell procedures on an outpatient basis. The entire process takes place within a few hours during two consecutive days at our state-of-the-art facility. During stem cell treatment for pulmonary fibrosis, our caring medical staff:

  • Harvests stem cells from a patient’s own blood or bone marrow
  • Separates the stem cells in an onsite lab
  • Reintroduces the stem cells into the patient’s body intravenously

At that point, the stem cells can travel through the bloodstream to reach the lungs, where they may begin to reduce inflammation and promote the natural healing process of damaged tissue. Because the stem cells are derived from the patient’s own body, the risks of rejection and other complications are virtually eliminated. More than 80 percent of people who undergo stem cell therapy at the Lung Institute have reported an improvement in their quality of life.

The Lung Institute is proud to be a world-recognized leader in regenerative medicine and stem cell research. The progress we’ve made to date allows us to provide our patients with an alternative pulmonary fibrosis treatment that can potentially improve their lung function and enhance their quality of life. If you are exploring treatment options for pulmonary fibrosis, you are encouraged to consider the Lung Institute. For more information on stem cell therapy for pulmonary fibrosis treatment, contact us at (800) 729-3065.

* All treatments performed at Lung Institute utilize autologous stem cells, meaning those derived from a patient's own body. No fetal or embryonic stem cells are utilized in Lung Institute's procedures. Lung Institute aims to improve patients' quality of life and help them breathe easier through the use of autologous stem cell therapy. To learn more about how stem cells work for lung disease, click here.

All claims made regarding the efficacy of Lung Institute's treatments as they pertain to pulmonary conditions are based solely on anecdotal support collected by Lung Institute. Individual conditions, treatment and outcomes may vary and are not necessarily indicative of future results. Testimonial participation is voluntary. Lung Institute does not pay for or script patient testimonials.

Under current FDA guidelines and regulations 1271.10 and 1271.15, the Lung Institute complies with all necessary requirements for operation. The Lung Institute is firmly in accordance with the conditions set by the FDA for exemption status and conducts itself in full accordance with current guidelines. Any individual who accesses Lung Institute's website for information is encouraged to speak with his or her primary physician for treatment suggestions and conclusive evidence. All information on this site should be used for educational and informational use only.

As required by Texas state law, the Lung Institute Dallas Clinic has received Institutional Review Board (IRB) approval from MaGil IRB, now Chesapeake IRB, which is fully accredited by the Association for the Accreditation of Human Research Protection Program (AAHRPP), for research protocols and stem cell procedures. The Lung Institute has implemented these IRB approved standards at all of its clinics nationwide. Approval indicates that we follow rigorous standards for ethics, quality, and protections for human research.